A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
Latest Information Update: 06 May 2025
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLANTIC
- Sponsors AstraZeneca
Most Recent Events
- 27 Apr 2025 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 28 Jun 2024 to 28 Feb 2025.
- 11 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.